167 results
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
;
voting or other rights, if any;
conversion, exchange and exercise prices, if any; and
important federal income tax considerations.
We may offer and sell … as parts of units;
a discussion of material United States federal income tax considerations of holding or exercising the warrants; and
any other
8-K
EX-10.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
Indebtedness.
(bb) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result … income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
8-K
EX-4.2
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant … and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
8-K
EX-4.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall … , the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required
424B5
cng2qwgkzlzwu86xkky
19 Apr 24
Prospectus supplement for primary offering
9:17am
8-K
EX-10.1
ab4ia3g genihlce
4 Apr 24
Entry into a Material Definitive Agreement
4:35pm
424B5
9hnubiue6q0crj5otshk
4 Apr 24
Prospectus supplement for primary offering
4:33pm
424B5
sl2wei l712
27 Mar 24
Prospectus supplement for primary offering
8:15am
8-K
EX-10.1
g6idkwv y2yk4a6pi
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
EX-4.1
wps7hd 4j1
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
EX-4.2
h48s xy5u
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
EX-99.1
azpf061bpgu1 jxp
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am